Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

35.06USD
7 Dec 2018
Change (% chg)

$-0.86 (-2.39%)
Prev Close
$35.92
Open
$35.86
Day's High
$36.39
Day's Low
$34.12
Volume
212,503
Avg. Vol
257,578
52-wk High
$73.90
52-wk Low
$17.40

Latest Key Developments (Source: Significant Developments)

Crispr Therapeutics And Maxcyte Expand Clinical And Commercial License Agreement Into Oncology
Friday, 9 Nov 2018 07:00am EST 

Nov 9 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND MAXCYTE EXPAND CLINICAL AND COMMERCIAL LICENSE AGREEMENT INTO ONCOLOGY.CRISPR THERAPEUTICS AG - WILL OBTAIN NON-EXCLUSIVE DEVELOPMENT AND COMMERCIAL-USE RIGHTS TO MAXCYTE'S CELL ENGINEERING PLATFORM.CRISPR THERAPEUTICS - GAINS ADDITIONAL RIGHTS TO MAXCYTE'S CELL ENGINEERING TECHNOLOGY TO DEVELOP CRISPR/CAS9-BASED CELL THERAPIES IN IMMUNO-ONCOLOGY.CRISPR THERAPEUTICS AG - MAXCYTE WILL RECEIVE MILESTONE AND SALES-BASED PAYMENTS IN ADDITION TO OTHER LICENSING FEES.  Full Article

Maxcyte, Crispr Therapeutics Expand Clinical, Commercial Oncology License Agreement
Friday, 9 Nov 2018 02:00am EST 

Nov 9 (Reuters) - CRISPR Therapeutics AG ::MAXCYTE INC - CRISPR THERAPEUTICS AND MAXCYTE EXPAND CLINICAL AND COMMERCIAL LICENSE AGREEMENT INTO ONCOLOGY.MAXCYTE INC - EXPANSION OF EXISTING RELATIONSHIP THAT WILL ALLOW CRISPR THERAPEUTICS TO DEPLOY MAXCYTE'S FLOW ELECTROPORATION TECHNOLOGY.  Full Article

Crispr Therapeutics Q3 Loss Per Share $1.07
Wednesday, 7 Nov 2018 04:33pm EST 

Nov 7 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - $487.3 MILLION IN CASH AS OF SEPTEMBER 30, 2018.CRISPR THERAPEUTICS AG - TARGETING INITIATION OF CLINICAL TRIAL FOR CTX110, TARGETING CD19+ MALIGNANCIES, IN 1H 2019.CRISPR THERAPEUTICS AG QTRLY LOSS PER SHARE $1.07.  Full Article

Crispr Therapeutics Says FDA Lifted Clinical Hold On Sickle Cell Disease Drug
Wednesday, 10 Oct 2018 06:28pm EDT 

Oct 10 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS, VERTEX SAYS FDA LIFTED CLINICAL HOLD ON IND APPLICATION FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS - COMPANIES REMAIN ON TRACK TO INITIATE A PHASE 1/2 CLINICAL STUDY IN SCD BY END OF 2018.  Full Article

CRISPR Therapeutics AG Files For Potential Mixed Shelf Offering
Wednesday, 19 Sep 2018 06:00pm EDT 

Sept 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AG FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares
Wednesday, 19 Sep 2018 04:08pm EDT 

Sept 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $200,000,000 OF ITS COMMON SHARES.  Full Article

Crispr Therapeutics, Intellia Therapeutics And Caribou Biosciences Provide Update On U.S Federal Circuit Decision
Monday, 10 Sep 2018 04:30pm EDT 

Sept 10 (Reuters) - Intellia Therapeutics Inc ::CRISPR THERAPEUTICS, INTELLIA THERAPEUTICS AND CARIBOU BIOSCIENCES PROVIDE UPDATE ON U.S FEDERAL CIRCUIT DECISION UPHOLDING THE RULING BY U.S. PATENT AND TRADEMARK OFFICE IN INTERFERENCE PROCEEDING RELATING TO CRISPR/CAS9 GENOME EDITING TECHNOLOGY.INTELLIA THERAPEUTICS INC - COMPANIES EXPECT USPTO WILL CONTINUE TO ISSUE PATENTS TO UC COVERING FOUNDATIONAL CRISPR/CAS9 TECHNOLOGY.  Full Article

Crispr Therapeutics Qtrly ‍​collaboration Revenue $32.3 Mln
Thursday, 8 Mar 2018 04:15pm EST 

March 8 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - QTRLY ‍​COLLABORATION REVENUE $32.3 MILLION VERSUS $2.3 MILLION.  Full Article

Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
Thursday, 4 Jan 2018 07:03pm EST 

Jan 4 (Reuters) - Crispr Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $22.75PER SHARE.  Full Article

Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​
Wednesday, 3 Jan 2018 06:15am EST 

Jan 3 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - ‍COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON SHARES​.  Full Article

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.